<DOC>
	<DOCNO>NCT00623558</DOCNO>
	<brief_summary>The aim study investigate efficacy safety cetuximab , docetaxel , cisplatin combination induction therapy locally advanced head neck squamous cell carcinoma .</brief_summary>
	<brief_title>Cetuximab Induction Treatment Head Neck Squamous Cell Carcinoma ( HNSCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Unresectable , locally advanced ( cT4b &amp; /or cN23 ) HNSCC ECOG performance status 01 Age 18 old 18 year Measurable disease RECIST criterion Having sign informed consent ALT AST &lt; 2.5 time ULN Serum albumin level ≥3.0g/dL Serum AKP &lt; 2.5 time ULN Bilirubin level &lt; 1.5mg/dL Serum creatinine &lt; 1.5 time ULN WBC &gt; 3000/mm3 , absolute neutrophil count ≥1500/mm3 , platelet &gt; 75,000/mm3 , Hb &gt; 9g/dl Previous cytotoxic chemotherapy HNSCC Radiotherapy target lesion within six month Previous EGFR pathwaytargeting therapy Prior surgery cancer ( exclude diagnostic biopsy within 4 week prior study entry ) Distant metastatic disease Heart failure , coronary artery disease , myocardial infarction within last 6 month Known allergy study treatment Pregnancy lactation period Any investigational agent within past 28 day Other previous malignancy within 5 year , except adequately treat situ cervical cancer , nonmelanoma skin cancer Legal incapacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>head neck neoplasm</keyword>
	<keyword>cetuximab</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cisplatin</keyword>
	<keyword>radiotherapy</keyword>
</DOC>